stockrow
Friday 6 November 2026
Export LFCR’s income statement to Excel — free account
Lifecore Biomedical, Inc.
LFCR Healthcare Drug Manufacturers Specialty & Generic
Lifecore Biomedical, Inc.’s revenue for fiscal 2025 (year ended May 2025) was $128.9 million, roughly unchanged from fiscal 2024.
- Revenue
- −18.6%
- EPS
- −1,700.0%
- Free cash flow
- +27,684.0%
- Total debt
- +15.3%
Quarter to September 2026, against a year earlier
6.37
0.03
−0.47%
Follow LFCR
Alert me
| May '25 | May '24 | May '23 | May '22 | May '21 | May '20 | May '19 | May '18 | May '17 | May '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 6 | 3 | 3 | 5 | 2 | 3 | 5 | 7 | — |
P/E ratio |
0.00 | 14.75 | 0.00 | 0.00 | 0.00 | 0.00 | 781.10 | 15.62 | 35.77 | 0.00 |
P/S ratio |
1.82 | 1.39 | 2.38 | 2.52 | 3.38 | 1.97 | 0.50 | 0.74 | 0.81 | 0.66 |
Altman Z-Score |
0.12 | 0.21 | 0.07 | 0.50 | 1.06 | 0.91 | 2.07 | 3.34 | 3.63 | 3.04 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 12.14 | 0.00 | 0.00 | 0.00 | 49.47 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.50) | (1.00) | (1.29) | (2.16) | 1.45 | 0.80 | 1.85 | 2.99 | 3.42 | 2.58 |
P/Operating CF |
47.55 | 20.42 | (108.47) | (510.82) | 58.08 | (24.89) | (196.87) | (745.19) | 57.36 | 21.85 |
Beneish M-Score |
(3.15) | (2.28) | (3.23) | (2.84) | (3.41) | (1.11) | (2.48) | (2.26) | (2.82) | (3.16) |
P/B ratio |
190.30 | 15.73 | 0.00 | 3.09 | 1.68 | 1.37 | 1.04 | 1.54 | 1.67 | 1.47 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 3.88 | 2.38 | 2.56 | 1.90 | 2.20 | 2.54 | 2.22 |
EV/Sales |
2.86 | 2.49 | 3.80 | 3.84 | 5.29 | 3.16 | 0.77 | 0.87 | 0.92 | 0.76 |
EV/EBITDA |
0.00 | 279.94 | 0.00 | 4.30 | 21.48 | 33.86 | 16.71 | 15.63 | 14.38 | 0.00 |
EV/Operating CF |
248.44 | (47.08) | (18.80) | (15.88) | 15.28 | (15.83) | 20.61 | 17.55 | 12.17 | 15.81 |
EV/FCF |
(69.88) | (9.26) | (8.46) | (6.32) | 19.00 | (7.01) | (10.16) | (27.38) | 55.76 | (11.52) |
Quick Ratio |
1.22 | 0.91 | 1.22 | 0.22 | 0.42 | 0.47 | 0.52 | 0.64 | 1.01 | 1.00 |
Current Ratio |
2.84 | 2.08 | 2.39 | 0.66 | 1.46 | 0.96 | 0.97 | 1.10 | 1.58 | 1.53 |
Net Debt/EBITDA |
(15.59) | (158.92) | (20.15) | 1.74 | 17.45 | 32.11 | 7.14 | 2.69 | 1.89 | (4.56) |
Debt/Assets |
63.50% | 59.02% | 65.69% | 53.93% | 38.55% | 35.16% | 28.70% | 18.02% | 15.05% | 17.85% |
Debt/Equity |
3.20 | 2.78 | 4.75 | 1.69 | 0.96 | 0.82 | 0.55 | 0.29 | 0.24 | 0.29 |
Asset Turnover |
0.52 | 0.51 | 0.39 | 0.29 | 0.19 | 0.30 | 1.21 | 1.37 | 1.34 | 1.38 |
Operating CF/Net income |
0.00 | 0.02 | 0.18 | 0.19 | (0.51) | 0.45 | 38.98 | 0.80 | 2.82 | (1.78) |
Capex/Depreciation |
(0.80) | (2.31) | (1.48) | (0.30) | (0.62) | (0.76) | (2.92) | (2.70) | (2.15) | (4.21) |
Interest Coverage |
(0.79) | (0.49) | (1.24) | (0.76) | (0.99) | (5.57) | 1.05 | 6.97 | 8.03 | (10.38) |
| (701.27%) | 339.11% | (238.21%) | (80.32%) | (14.89%) | (15.24%) | 0.16% | 10.33% | 4.81% | (5.38%) | |
| (17.98%) | 4.73% | (37.70%) | (30.02%) | (6.19%) | (7.20%) | 0.09% | 6.51% | 3.02% | (3.38%) | |
ROIC |
(5.64%) | (2.83%) | (7.46%) | (3.14%) | (1.39%) | (3.84%) | 0.82% | 2.63% | 3.32% | (4.89%) |
Return on Tangible Assets |
(24.04%) | 6.28% | (52.69%) | (198.64%) | (19.37%) | (20.64%) | 0.21% | 14.75% | 6.50% | (7.72%) |
Average Days of Receivables |
81.26 | 77.07 | 102.58 | 125.68 | 149.91 | 173.77 | 45.54 | 37.51 | 35.66 | 35.52 |
Research and Development Expense of Revenue |
6.41% | 6.69% | 8.46% | 7.05% | 6.63% | 4.74% | 2.06% | 2.44% | 2.02% | 1.52% |
Selling, General and Administrative Expense of Revenue |
34.18% | 31.55% | 37.74% | 31.15% | 27.48% | 25.41% | 11.13% | 9.91% | 11.17% | 9.68% |
Intangible Assets out of Total Assets |
0.08 | 0.07 | 0.07 | 0.07 | 0.12 | 0.20 | 0.24 | 0.19 | 0.22 | 0.21 |
Share Based Compensation of Revenue |
7.88% | 4.83% | 3.50% | 2.34% | 3.33% | 1.51% | 0.64% | 0.84% | 0.84% | 0.73% |
Graham Net Nets |
(0.42) | (0.67) | (0.51) | (0.23) | (0.45) | (0.48) | (0.41) | (0.14) | (0.13) | (0.14) |
Graham Number |
0.00 | 1.82 | 3.19 | 0.00 | 0.00 | 0.00 | 1.65 | 13.65 | 8.58 | 0.00 |
Earnings Yield |
(17.47%) | 6.78% | (39.04%) | (34.85%) | (9.60%) | (12.09%) | 0.13% | 6.40% | 2.80% | (3.72%) |
Free Cash Flow Yield |
(2.24%) | (19.38%) | (18.93%) | (24.16%) | 8.24% | (22.84%) | (15.01%) | (4.31%) | 2.02% | (10.10%) |
Revenue per Share |
3.70 | 4.21 | 3.45 | 3.78 | 3.44 | 5.49 | 19.66 | 19.04 | 17.22 | 17.63 |
Operating CF per Share |
(0.01) | 0.01 | (0.58) | (0.77) | 0.56 | (0.58) | 0.56 | 0.72 | 1.09 | 0.77 |
Capex per Share |
(0.18) | (0.60) | (0.72) | (0.98) | (0.42) | (0.83) | (1.57) | (1.22) | (0.84) | (1.46) |
Free Cash Flow per Share |
(0.19) | (0.60) | (1.30) | (1.74) | 0.14 | (1.42) | (1.00) | (0.50) | 0.25 | (0.70) |
Cash per Share |
0.24 | 0.28 | 0.64 | 0.03 | 0.04 | 0.01 | 0.04 | 0.11 | 0.22 | 0.37 |
Shareholders Equity per Share |
1.36 | 1.77 | 1.17 | 2.98 | 6.92 | 7.92 | 9.53 | 9.17 | 8.36 | 7.85 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.36 | 1.77 | 1.17 | 2.98 | 6.92 | 7.92 | 9.53 | 9.17 | 8.36 | 7.85 |
Free Cash Flow |
(6.62) | (18.14) | (38.92) | (51.39) | 4.16 | (41.29) | (28.45) | (13.71) | 6.92 | (18.81) |
Working Capital |
55.50 | 42.16 | 54.59 | (59.91) | 46.43 | (7.28) | (4.05) | 8.69 | 29.83 | 29.96 |
Capital Expenditures |
(6.41) | (18.39) | (21.48) | (28.80) | (12.31) | (24.25) | (44.47) | (33.49) | (22.92) | (39.57) |
Net Current Asset Value |
(106.23) | (119.02) | (124.58) | (70.21) | (151.82) | (153.16) | (115.91) | (55.08) | (49.18) | (44.00) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 78.40 | 33.73 | 29.34 | 0.00 |
Capex to Sales |
0.05 | 0.14 | 0.21 | 0.26 | 0.12 | 0.15 | 0.08 | 0.06 | 0.05 | 0.08 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.38 | 28.57 | 26.03 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.06 | 0.05 | 0.11 | 0.81 | 0.17 | 0.17 | 0.08 | 0.08 | 0.08 | 0.08 |
Cash ROIC |
(3.19%) | (8.55%) | (17.63%) | (21.69%) | 1.05% | (9.79%) | (6.77%) | (4.18%) | 2.40% | (6.64%) |
Accounts Receivable Turnover |
4.62 | 4.57 | 3.07 | 2.79 | 1.72 | 2.20 | 9.03 | 10.51 | 10.18 | 10.27 |
Accounts Payable Turnover |
7.21 | 4.50 | 4.30 | 4.94 | 1.82 | 2.29 | 10.75 | 15.07 | 14.09 | 12.44 |
Inventory Turnover |
2.45 | 2.14 | 1.96 | 1.46 | 0.96 | 2.00 | 11.09 | 16.09 | 15.89 | 16.22 |
Average Days of Payables |
33.88 | 68.99 | 107.13 | 65.47 | 96.05 | 156.21 | 41.34 | 28.38 | 22.92 | 27.50 |
Days of Inventory on Hand |
133.07 | 168.87 | 198.01 | 181.98 | 371.71 | 200.56 | 41.46 | 26.05 | 22.07 | 22.72 |
Average Receivables |
27.89 | 28.05 | 33.67 | 39.87 | 58.82 | 72.89 | 61.72 | 49.89 | 46.15 | 46.44 |
Average Payables |
12.28 | 19.22 | 17.52 | 14.63 | 33.97 | 52.81 | 44.32 | 29.60 | 27.72 | 32.96 |
Average Inventory |
36.14 | 40.41 | 38.42 | 49.54 | 64.69 | 60.22 | 42.98 | 27.72 | 24.58 | 25.28 |
Average Assets |
246.65 | 253.75 | 264.12 | 388.81 | 522.12 | 530.20 | 461.90 | 381.66 | 350.63 | 344.56 |
Average Common Equity |
6.33 | 3.54 | 41.80 | 145.30 | 216.91 | 250.59 | 261.35 | 240.36 | 220.25 | 216.23 |
Columns are period end dates · fundamentals updated 4 Nov 2026